MA02.07 Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial

医学 消炎药 可视模拟标度 随机对照试验 肺癌 临床终点 内科学 生活质量(医疗保健) 书呆子 性能状态 麻醉 胃肠病学 癌症 化疗 止吐药 疾病 格尔德 护理部 回流
作者
K. Prabhash,Vanita Noronha,Atanu Bhattacharjee,VijayM Patil,Amit Joshi,S. Shah,Srinivasaraghavan Kannan,S. Ishi
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:13 (10): S360-S360 被引量:1
标识
DOI:10.1016/j.jtho.2018.08.327
摘要

Cough is a distressing symptom in patients with lung cancer. Effective management of cough leads to improvement in quality of life (QoL) and optimal palliative care. Aprepitant, a centrally acting neurokinin-1 inhibitor, has been shown in a pilot study to significantly decrease the cough frequency. A randomized open-label study in patients with advanced lung cancer with cough for over 2 weeks despite therapy with a cough suppressant, with an ECOG performance status 0 to 2. Patients were randomized 1: 1 to Arm A: aprepitant 125 mg orally on day 1, followed by 80 mg orally on days 2 to 7 along with physician’s choice of antitussive therapy. Patients on Arm B received physician’s choice of antitussive therapy. Patients were evaluated at baseline and then on days 3, 7, 9 and 12. Primary efficacy endpoint was subjective improvement in cough, measured with the Visual Analog Scale (VAS) and the Manchester Cough in Lung Cancer Scale (MCLCS). Secondary endpoints included toxicity and QoL, measured by the EORTC QLQ-C30 and LC13. The trial was approved by the` institutional IEC and registered with (CTRI/2017/05/008691). Between June 2017 and June 2018, 128 patients were randomized: 64 to each arm. The median age was 53 yrs, 65% male, 64% never-smokers, 82% had adenocarcinoma. 88% had Stage IV disease; 80% had PS 1 and 20% PS 2. The median duration of cough was 90 days. VAS scores at baseline and day 9 was 67.93, 38.50 in Arm A and 63.15, 48.57 Arm B , with p<0.001 and the MCLCS scores at baseline and day 9 was 30.03, 22.32 in Arm A and 27.53, 23.80 Arm B , with p<0.001. Overall, there was no significant difference in the QoL scores in patients in the two arms, however there was a significant improvement in the cough-specific QoL domain in the patients on the aprepitant arm, p=0.017. There was no increase in the grade 3 and higher adverse events in the patients on the aprepitant arm. Aprepitant led to a significant improvement in cough in patients with advanced lung cancer, with no increase in severe side-effects. Aprepitant should be considered as one of the treatment options for cough in lung cancer patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
leeom发布了新的文献求助10
2秒前
Timo干物类完成签到,获得积分10
2秒前
北冥有鱼给北冥有鱼的求助进行了留言
2秒前
2秒前
王冉冉发布了新的文献求助30
2秒前
Ava应助易拉罐采纳,获得10
3秒前
隐形曼青应助无心的土豆采纳,获得10
3秒前
乐于助人大好人完成签到 ,获得积分10
3秒前
ZZQ完成签到,获得积分10
7秒前
量子星尘发布了新的文献求助10
7秒前
Lina HE完成签到 ,获得积分10
7秒前
852应助科研通管家采纳,获得10
7秒前
Ava应助科研通管家采纳,获得10
8秒前
ED应助科研通管家采纳,获得10
8秒前
领导范儿应助科研通管家采纳,获得10
8秒前
8秒前
Akim应助科研通管家采纳,获得10
8秒前
进步完成签到,获得积分10
8秒前
852应助科研通管家采纳,获得10
8秒前
ED应助科研通管家采纳,获得10
8秒前
英俊的铭应助科研通管家采纳,获得10
8秒前
SciGPT应助科研通管家采纳,获得10
8秒前
Akim应助科研通管家采纳,获得10
8秒前
iNk应助dh采纳,获得20
8秒前
orixero应助科研通管家采纳,获得30
8秒前
思源应助科研通管家采纳,获得10
8秒前
wanci应助科研通管家采纳,获得10
8秒前
赘婿应助科研通管家采纳,获得10
9秒前
wanci应助科研通管家采纳,获得10
9秒前
李健应助科研通管家采纳,获得10
9秒前
9秒前
9秒前
wanci应助科研通管家采纳,获得10
9秒前
9秒前
9秒前
9秒前
9秒前
科研通AI2S应助科研通管家采纳,获得10
9秒前
9秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038569
求助须知:如何正确求助?哪些是违规求助? 3576279
关于积分的说明 11374944
捐赠科研通 3305979
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815048